Guide de travaux pratiques · Axe de l'hormone de croissance
What Is CJC-1295 With DAC? Albumin-Binding GHRH Analogue Research Overview
What is CJC-1295 With DAC? It is a growth hormone-releasing hormone analogue carrying a drug affinity complex, a maleimide group that bonds covalently to serum albumin and extends its time in circulation to days. This guide explains that chemistry, the published pharmacokinetic findings, and how the compound differs from the no-DAC form.
Points clés à retenir
- CJC-1295 is a tetrasubstituted hGRF(1-29) with an N-epsilon-3-maleimidopropionamide lysine at the C terminus, which reacts with albumin to form a covalent conjugate.
- In rats, it produced a four-fold greater GH area under the curve over two hours than hGRF(1-29) and persisted in plasma beyond 72 hours (Jetté et al., 2005).
- In healthy adults, a single dose raised mean GH 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9-11 days (Teichman et al., 2006).
- Pulsatile GH secretion was preserved while trough levels rose, an experimental variable that separates it from the short-acting no-DAC peptide.
Qu'est-ce que le CJC-1295 avec DAC ?
So, what is CJC-1295 With DAC? CJC-1295 is the long-acting GHRH analogue described by Jetté et al. (2005, Endocrinology): a tetrasubstituted form of hGRF(1-29) with an N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus. That group is the drug affinity complex (DAC). Researchers also write it DAC:GRF. The shorter-acting peptide without this group is covered in What is CJC-1295 No DAC.
À usage exclusivement scientifique. Cette présentation synthétise les résultats publiés issus de recherches en laboratoire et sur des animaux. Baltic Peptides fournit ce composé à des chercheurs qualifiés pour des recherches in vitro et précliniques ; il ne s'agit pas d'un médicament et il n'est pas destiné à un usage humain ou vétérinaire.
Structure chimique et caractéristiques techniques
| Biens immobiliers | Value (as listed on the Baltic Peptides product page) |
|---|---|
| Core peptide | [D-Ala2, Gln8, Ala15, Leu27]-GHRH(1-29) |
| DAC | Lys30 carrying an epsilon-maleimidopropionyl group |
| Formule moléculaire | C165H269N47O46 |
| Poids moléculaire | 3 647,2 g/mol |
| Numéro CAS | 446262-90-4 |
The formula is consistent with the no-DAC peptide plus one lysine residue plus the maleimidopropionyl group, which I checked by adding the atoms. I could not confirm the mass or CAS number in PubChem, so they are given as supplier values; confirm identity from the batch mass. The maleimide hydrolyses in water to a ring-opened form that adds 18 Da and can no longer bind albumin, so mass spectrometry also reports on maleimide integrity.
Historique des découvertes et de la recherche
CJC-1295 was developed using a drug affinity complex platform. Jetté et al. (2005, Endocrinology) showed in rats that the conjugate was found bound to albumin, was present in plasma beyond 72 hours, and produced a four-fold larger GH response than hGRF(1-29).
Teichman et al. (2006) then studied it in healthy adults, and a once-daily dosing study and Ionescu and Frohman (2006) followed.
Mechanism: albumin conjugation and GHRH receptor activation
Covalent albumin binding
The maleimide reacts with the free thiol of cysteine-34 on circulating albumin to form a stable thioether bond. The albumin-bound peptide remains an agonist at the GHRH receptor but is protected from rapid clearance and degradation.
Receptor signalling
As with native GHRH, receptor activation on pituitary somatotrophs raises cAMP and stimulates GH release. The altered feature is exposure time, not receptor selectivity.
Principaux domaines de recherche
- Pharmacokinetics: albumin conjugation as a model of half-life extension.
- Chronic receptor stimulation: adaptation and desensitisation under sustained agonism.
- GH and IGF-I dynamics: trough and mean levels versus pulsatility.
- Bioconjugation chemistry: maleimide-thiol reactions in peptide design.
Ce que révèlent réellement les études publiées
| Type de preuve | Ce qui est rapporté |
|---|---|
| Rats | Four-fold greater GH AUC than hGRF(1-29) over 2 hours; plasma presence beyond 72 hours (Jetté et al. (2005, Endocrinology)). |
| Healthy adults | Single dose: GH up 2- to 10-fold for six days or more and IGF-I up 1.5- to 3-fold for 9-11 days; IGF-I stayed above baseline for up to 28 days after repeated dosing (Teichman et al. (2006)). |
| Pulsatility | Pulse frequency and magnitude were unaltered, while basal GH rose 7.5-fold and mean GH 46% (Ionescu and Frohman (2006)). |
| Demi-vie | The Ionescu and Frohman abstract gives 8 days; Baltic Peptides cites 5.8-8.1 days for Teichman et al. |
These are controlled studies in small numbers of healthy volunteers. The authors of the 2006 study described the compound as safe and relatively well tolerated at the doses tested, which does not establish long-term safety.
Limites scientifiques et questions en suspens
- Human studies were small, short and performed more than 15 years ago.
- Sustained receptor stimulation changes the GH profile, so findings do not apply to pulsatile analogues.
- The compound has no EMA or FDA approval, and early clinical studies do not change its research-only status.
- Supplier masses and CAS numbers could not be cross-checked against PubChem.
- Les analogues de la GHRH sont interdits dans le sport en vertu de la Liste des substances interdites de l'AMA.
Considérations relatives aux analyses et aux travaux de laboratoire
Mass spectrometry should show the intact conjugate at about 3647 Da and should distinguish it from the hydrolysed, ring-opened form (+18 Da) that cannot bind albumin. HPLC should resolve truncated sequences. Because the maleimide hydrolyses in water, faster at higher pH and temperature, handling should limit time in aqueous solution; this is a stability consideration for experiments rather than a procedure.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the CJC-1295 With DAC product page.
Sources et lectures complémentaires
- Jetté L. et al. (2005). Les bioconjugués du facteur de libération de l'hormone de croissance humaine (hGRF) 1-29-albumine activent le récepteur du GRF sur l'hypophyse antérieure chez le rat : identification du CJC-1295 comme analogue du GRF à action prolongée. Endocrinology. PubMed
- Teichman S.L. et al. (2006). Stimulation prolongée de la sécrétion de l'hormone de croissance et du facteur de croissance analogue à l'insuline I par le CJC-1295, un analogue à action prolongée de l'hormone libérant la GH, chez des adultes en bonne santé. J Clin Endocrinol Metab 91(3) : 799-805. PubMed
- Ionescu M. and Frohman L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. PubMed
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog (2006). PubMed
Tous les produits de la gamme « Baltic Peptides » sont destinés exclusivement à la recherche en laboratoire. Il ne s'agit ni de médicaments, ni de compléments alimentaires, ni d'aliments, et ils ne sont pas destinés à être utilisés chez l'homme ou chez l'animal. Cet article résume les recherches publiées à des fins purement pédagogiques et ne décrit aucune utilisation chez l'homme.
FAQ
Questions fréquentes
Qu'est-ce que le CJC-1295 avec DAC ?
What does the drug affinity complex do?
What is the half-life of CJC-1295 With DAC?
What did the 2006 human study find?
Does CJC-1295 With DAC change GH pulsatility?
How is CJC-1295 With DAC different from CJC-1295 No DAC?
Is CJC-1295 With DAC an approved medicine?
Continuez à lire
Lectures complémentaires
CJC-1295 avec DAC
Current batches, formats and the COA for CJC-1295 With DAC.
Qu'est-ce que le CJC-1295 No DAC ?
The short-acting peptide without the albumin-binding group.
Tout savoir sur les mélanges de peptides
Pourquoi la recherche sur les composants ne permet-elle pas de définir une formulation combinée ?
Research-grade CJC-1295 With DAC, tested before it ships
HPLC s indépendantes et résultats de spectrométrie de masse pour chaque lot expédié depuis l'UE.
